New hybrid nanoparticles offer precise cell targeting

A research team drawn from the National Institute of Standards and Technology, the University of Maryland and the FDA has developed a method to combine two substances into a hybrid nanoscale particle capable of precise drug payload delivery through a target cell's membrane.

To get the hybrid particle the team combined a phospholipid membrane "bubble" called a liposome and particles of hydrogel, a water-filled network of polymer chains. The hybrid combines the targeting abilities of liposomes with the durability of the hydrogel, overcoming a tendency to rupture without the hydrogel's tendency to clump together.

The liposome-hydrogel hybrid vesicles are irradiated, adding strength to the delivery particles, which can be loaded with a therapeutic payload during the manufacturing process.

- check out the report from Science Daily

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.